Year: 2021

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Atlanta, GA and virtually from December 11-14, 2021. “As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. “The data will feature our novel allogeneic technology designed to overcome...

Expects to sanction approximately $7 billion of new capital projects in 2021Modified dividend growth outlook enhances ability to fund substantial new growth opportunities CALGARY, Alberta, Nov. 05, 2021 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced net income attributable to common shares for third quarter 2021 of $779 million or $0.80 per share compared to net income of $904 million or $0.96 per share for the same period in 2020. Comparable earnings for third quarter 2021 were $1.0 billion or $0.99 per common share compared to $893 million or $0.95 per common share in 2020. TC Energy’s Board of Directors also declared a quarterly dividend of $0.87 per common share for the quarter ending December 31, 2021, equivalent to $3.48 per common share on an annualized basis. “During...

Achiko to develop dengue fever diagnostic test by applying its DNA aptamer technology platform. This is another promising application of the technology that Achiko is already successfully using to diagnose Covid-19. The dengue virus infects about 400 million people every year and is endemic to where 3.6 billion (40%) of the world’s population live. Achiko is developing a range of diagnostic tests for other pathogenic diseases applying DNA aptamer technology.ZURICH, Switzerland, Nov. 05, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) a global healthtech company currently developing technologies that seek to deliver rapid, affordable diagnostic testing for Covid-19 and a range of other pathogenic diseases announced today the development of...

Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HS In Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum, 6 out of 7 patients in highest dose cohort showed clinical remission and closure of target ulcer InflaRx awarded grant by German government of up to €43.7 million to advance development of vilobelimab for treatment of severe COVID-19 patients Enrollment completed in Phase III part of Phase II/III study evaluating vilobelimab in severe COVID-19; Topline results expected in Q1 2022 Cash, cash equivalents and financial assets of approximately €120.6 million as of September 30, 2021JENA, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage...

ST. CLOUD, Minn., Nov. 05, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that NFI subsidiary New Flyer of America Inc. (“New Flyer”) has been awarded a zero-emission contract from California’s SunLine Transit Agency (“SunLine”) for five forty-foot fuel cell-electric Xcelsior CHARGE H2™ heavy-duty transit buses. The purchase follows SunLine’s previous 2020 order for five Xcelsior CHARGE H2™ buses and brings SunLine’s total zero-emission fleet to 26 fuel cell-electric vehicles (“EVs”). SunLine provides bus service in the Coachella Valley, delivering over four million annual passenger trips. This hydrogen bus order, and SunLine’s previous 2020 zero-emission order, are supported by Federal Transit...

The first dispensary in Illinois to receive approval and relocate, Zen Leaf St. Charles moved from its former location in a nearby business park to a prime retail space that offers improved visibility with an expanded footprint and additional parking capacity. The combined medical and adult-use dispensary is now located on the high-traffic retail corridor of Main Street in St. Charles, which saw average daily traffic of nearly 33,0001 cars in pre-pandemic 2019. Zen Leaf St. Charles, operational since 2015, is one of Illinois’ original 55 dispensaries and among the state’s highest volume storefronts relative to patient count.CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) — Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the reopening of Zen Leaf St....

Company Ended the Quarter With Cash of Approximately $559 Million NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal first quarter ended September 30, 2021. Immunovant ended the quarter with approximately $559 million in cash. Financial Highlights for Fiscal Second Quarter Ended September 30, 2021: R&D Expenses: Research and development expenses were $21.4 million for the three months ended September 30, 2021, compared to $12.0 million for the three months ended September 30, 2020. The year-over-year increase primarily reflected higher contract manufacturing costs and personnel-related expenses (including stock-based compensation), reflecting...

Sets Baseline and Provides SASB, GRI Core and SDG Disclosures WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website. Repligen’s 2020 Sustainability Report provides an overview of the Company’s environmental, social and governance (ESG) performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation’s SASB Medical Equipment and Supplies Standard, the Global Reporting Initiative (GRI) Standards Core option, and the United Nations (UN) Sustainable Development Goals (SDGs) as informed by the Company’s materiality assessment. As a participant of the United Nations Global Compact (UNGC) since July 2020, this report also serves to fulfill Repligen’s...

Raising 2021 adjusted EBITDA, operating earnings and distributable cash flow guidance Delivering 10% adjusted EBITDA growth and 12% operating earnings growth from 2020 original guidance Executing on investment opportunities that will deliver distinctive future growth Discusses industry-first carbon-neutral expansionDETROIT, Nov. 05, 2021 (GLOBE NEWSWIRE) — DT Midstream, Inc. [www.dtmidstream.com] (NYSE: DTM) today announced third quarter 2021 reported net income of $74 million, or $0.77 per diluted share. For the third quarter of 2021, operating earnings were $75 million and adjusted EBITDA was $188 million. Reconciliations of operating earnings, operating EPS and adjusted EBITDA (non-GAAP measures) to reported net income are included at the end of this news release. “Our third quarter results and increased 2021 guidance...

Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® will be featured in a poster presentation during the 2021 Virtual International Conference on ADHD, co-hosted by Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) with the ADHD Coaches Organization (ACO), and the Attention Deficit Disorder Association (ADDA), taking place November 4-6, 2021. The poster, titled, “Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated...